Morgan B Slater1,2, Andrea Gruneir3,4,5,6, Paula A Rochon4,5,6,7, Andrew W Howard2,5,8,9, Gideon Koren10, Christopher S Parshuram11,12,13,14,15. 1. Department of Critical Care Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. 2. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada. 3. Department of Family Medicine, University of Alberta, Edmonton, AB, Canada. 4. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 5. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 6. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 7. Department of Medicine, University of Toronto, Toronto, ON, Canada. 8. Division of Orthopaedic Surgery, The Hospital for Sick Children, Toronto, ON, Canada. 9. Department of Surgery, University of Toronto, Toronto, ON, Canada. 10. Department of Paediatrics, University of Toronto, Toronto, ON, Canada. 11. Department of Critical Care Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada. chris@sickkids.ca. 12. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada. chris@sickkids.ca. 13. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. chris@sickkids.ca. 14. Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON, Canada. chris@sickkids.ca. 15. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada. chris@sickkids.ca.
Abstract
BACKGROUND: Nephrotoxic medications are a common cause of acute kidney injury (AKI). Critically ill children receive more medication than other inpatients; however, the risk of nephrotoxic medication-induced AKI in these children is not well understood. OBJECTIVE: The aim of this study was to determine the association between exposure to nephrotoxic medications in the intensive care unit (ICU) and the development of AKI amongst critically ill children, adjusting for differences in underlying risk. METHODS: We conducted a nested case-control study among a cohort of patients admitted to a paediatric intensive care unit between January 2006 and June 2009. Cases were identified according to the RIFLE criteria. Using incidence density sampling, controls were matched 1:1 according to pre-ICU nephrotoxic drug exposure. Administration of nephrotoxic medications and other known risk factors of AKI were evaluated during the ICU stay prior to the diagnosis of AKI. RESULTS: A total of 914 patients in the cohort developed AKI and had an identifiable matched control. Eighty-seven percent of cases and 74% of controls were exposed to one or more nephrotoxic medications in the ICU during the study period. Furosemide (administered to 67.8% of patients), vancomycin (28.7%), and gentamicin (21.4%) were the most frequently administered nephrotoxic drugs. Patients who developed AKI were more likely to be exposed to at least one nephrotoxic medication and risk increased with increasing number of nephrotoxic medications. Ganciclovir (adjusted odds ratio [AOR] 4.7; 95% CI 1.7-13.0), furosemide (AOR 1.9; 95% CI 1.4-2.4), and gentamicin (AOR 1.8; 95% CI 1.4-2.4) significantly increased the odds of developing AKI after adjusting for underlying differences in risk factors of AKI. CONCLUSION: This is the first study to assess the association between risk-adjusted nephrotoxic medication exposure and the development of AKI in critically ill children. Nephrotoxic medication exposure was common amongst children in the ICU and we found AKI was associated with the administration of specific drugs after adjustment for important risk factors.
BACKGROUND:Nephrotoxic medications are a common cause of acute kidney injury (AKI). Critically illchildren receive more medication than other inpatients; however, the risk of nephrotoxic medication-induced AKI in these children is not well understood. OBJECTIVE: The aim of this study was to determine the association between exposure to nephrotoxic medications in the intensive care unit (ICU) and the development of AKI amongst critically illchildren, adjusting for differences in underlying risk. METHODS: We conducted a nested case-control study among a cohort of patients admitted to a paediatric intensive care unit between January 2006 and June 2009. Cases were identified according to the RIFLE criteria. Using incidence density sampling, controls were matched 1:1 according to pre-ICU nephrotoxic drug exposure. Administration of nephrotoxic medications and other known risk factors of AKI were evaluated during the ICU stay prior to the diagnosis of AKI. RESULTS: A total of 914 patients in the cohort developed AKI and had an identifiable matched control. Eighty-seven percent of cases and 74% of controls were exposed to one or more nephrotoxic medications in the ICU during the study period. Furosemide (administered to 67.8% of patients), vancomycin (28.7%), and gentamicin (21.4%) were the most frequently administered nephrotoxic drugs. Patients who developed AKI were more likely to be exposed to at least one nephrotoxic medication and risk increased with increasing number of nephrotoxic medications. Ganciclovir (adjusted odds ratio [AOR] 4.7; 95% CI 1.7-13.0), furosemide (AOR 1.9; 95% CI 1.4-2.4), and gentamicin (AOR 1.8; 95% CI 1.4-2.4) significantly increased the odds of developing AKI after adjusting for underlying differences in risk factors of AKI. CONCLUSION: This is the first study to assess the association between risk-adjusted nephrotoxic medication exposure and the development of AKI in critically illchildren. Nephrotoxic medication exposure was common amongst children in the ICU and we found AKI was associated with the administration of specific drugs after adjustment for important risk factors.
Authors: Andrew K Roy; Catherine Mc Gorrian; Cecelia Treacy; Edel Kavanaugh; Alice Brennan; Niall G Mahon; Patrick T Murray Journal: Cardiorenal Med Date: 2013-02-26 Impact factor: 2.041
Authors: Suchitra Rao; Mark J Abzug; Phyllis Carosone-Link; Tori Peterson; Jason Child; Georgette Siparksy; Danielle Soranno; Melissa A Cadnapaphornchai; Eric A F Simões Journal: J Pediatr Date: 2015-02-21 Impact factor: 4.406
Authors: Raymond K Hsu; Charles E McCulloch; R Adams Dudley; Lowell J Lo; Chi-yuan Hsu Journal: J Am Soc Nephrol Date: 2012-12-06 Impact factor: 10.121
Authors: Edward D Siew; Michael E Matheny; T Alp Ikizler; Julie B Lewis; Randolph A Miller; Lemuel R Waitman; Alan S Go; Chirag R Parikh; Josh F Peterson Journal: Kidney Int Date: 2009-12-30 Impact factor: 10.612
Authors: Omar Alkandari; K Allen Eddington; Ayaz Hyder; France Gauvin; Thierry Ducruet; Ronald Gottesman; Véronique Phan; Michael Zappitelli Journal: Crit Care Date: 2011-06-10 Impact factor: 9.097
Authors: Kevin J Downes; Molly Hayes; Julie C Fitzgerald; Gwendolyn M Pais; Jiajun Liu; Nicole R Zane; Stuart L Goldstein; Marc H Scheetz; Athena F Zuppa Journal: J Antimicrob Chemother Date: 2020-01-01 Impact factor: 5.790
Authors: Amanda M Uber; Maria E Montez-Rath; David M Kwiatkowski; Catherine D Krawczeski; Scott M Sutherland Journal: Pediatr Nephrol Date: 2018-07-09 Impact factor: 3.714
Authors: Emily L Joyce; Sandra L Kane-Gill; Priyanka Priyanka; Dana Y Fuhrman; John A Kellum Journal: J Am Soc Nephrol Date: 2019-09-09 Impact factor: 10.121
Authors: Steven L Rathgeber; Adrija Chakrabarti; Eva Kapravelou; Nicole Hemphill; Christine Voss; Cherry Mammen; Peter Skippen; Kevin C Harris Journal: J Am Heart Assoc Date: 2021-10-08 Impact factor: 5.501
Authors: Matthew P Gray; Erin F Barreto; Diana J Schreier; John A Kellum; Kangho Suh; Kianoush B Kashani; Andrew D Rule; Sandra L Kane-Gill Journal: Drug Saf Date: 2022-04-07 Impact factor: 5.228